NasdaqCM - Nasdaq Real Time Price USD

RedHill Biopharma Ltd. (RDHL)

0.4253 -0.0158 (-3.58%)
As of 1:27 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,530.0000
6,530.0000
61,800.0000
85,757.0000
64,359.0000
Cost of Revenue
3,459.0000
3,459.0000
33,337.0000
49,406.0000
36,892.0000
Gross Profit
3,071.0000
3,071.0000
28,463.0000
36,351.0000
27,467.0000
Operating Expense
-9,561.0000
-9,561.0000
71,307.0000
117,486.0000
91,151.0000
Operating Income
12,632.0000
12,632.0000
-42,844.0000
-81,135.0000
-63,684.0000
Net Non Operating Interest Income Expense
-2,158.0000
-2,158.0000
-42,207.0000
-16,581.0000
-12,574.0000
Other Income Expense
13,442.0000
13,442.0000
13,382.0000
-28.0000
85.0000
Pretax Income
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Net Income Common Stockholders
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Diluted NI Available to Com Stockholders
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Basic EPS
4.00
--
-48.00
-84.00
-79.35
Diluted EPS
4.00
--
-48.00
-84.00
-79.35
Basic Average Shares
6,478.0550
--
1,540.7480
1,163.1820
959.9540
Diluted Average Shares
6,478.0550
--
1,540.7480
1,163.1820
959.9540
Total Operating Income as Reported
12,632.0000
12,632.0000
-42,844.0000
-81,135.0000
-63,684.0000
Total Expenses
-6,102.0000
-6,102.0000
104,644.0000
166,892.0000
128,043.0000
Net Income from Continuing & Discontinued Operation
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Normalized Income
13,565.6600
13,565.6600
-85,051.0000
-97,716.0000
-76,258.0000
Interest Income
94.0000
94.0000
140.0000
51.0000
176.0000
Interest Expense
367.0000
367.0000
41,333.0000
16,567.0000
12,450.0000
Net Interest Income
-2,158.0000
-2,158.0000
-42,207.0000
-16,581.0000
-12,574.0000
EBIT
24,283.0000
24,283.0000
-30,336.0000
-81,177.0000
-63,723.0000
EBITDA
26,273.0000
26,273.0000
-22,182.0000
-63,028.0000
-54,978.0000
Reconciled Cost of Revenue
3,459.0000
3,459.0000
33,337.0000
49,406.0000
36,892.0000
Reconciled Depreciation
1,990.0000
1,990.0000
8,154.0000
18,149.0000
8,745.0000
Net Income from Continuing Operation Net Minority Interest
23,916.0000
23,916.0000
-71,669.0000
-97,744.0000
-76,173.0000
Total Unusual Items Excluding Goodwill
13,442.0000
13,442.0000
13,382.0000
-28.0000
85.0000
Total Unusual Items
13,442.0000
13,442.0000
13,382.0000
-28.0000
85.0000
Normalized EBITDA
12,831.0000
12,831.0000
-35,564.0000
-63,000.0000
-55,063.0000
Tax Rate for Calcs
0.0002
0.0002
--
--
--
Tax Effect of Unusual Items
3,091.6600
3,091.6600
--
--
--
12/31/2020 - 1/7/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BFRI Biofrontera Inc.
1.4701
+2.09%
 
SBFM Sunshine Biopharma, Inc.
1.2150
-15.63%
 
KMDA Kamada Ltd.
5.07
-0.63%
 
PTPI Petros Pharmaceuticals, Inc.
0.6550
-1.47%
 
HUGE FSD Pharma Inc.
0.4796
-1.92%
 
SXTC China SXT Pharmaceuticals, Inc.
1.0902
+2.85%
 
AKAN Akanda Corp.
0.0903
-1.10%
 
PRFX PainReform Ltd.
0.8510
-3.17%
 
FLGC Flora Growth Corp.
1.7500
+6.71%
 
YCBD cbdMD, Inc.
0.9846
+0.98%